MetLife Investment Management LLC Grows Stock Holdings in scPharmaceuticals Inc. (NASDAQ:SCPH)

MetLife Investment Management LLC boosted its holdings in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) by 135.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,974 shares of the company’s stock after purchasing an additional 9,752 shares during the quarter. MetLife Investment Management LLC’s holdings in scPharmaceuticals were worth $77,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. BNP Paribas Financial Markets raised its stake in scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after purchasing an additional 3,101 shares in the last quarter. Balanced Rock Investment Advisors LLC raised its stake in scPharmaceuticals by 10.3% during the second quarter. Balanced Rock Investment Advisors LLC now owns 63,130 shares of the company’s stock valued at $275,000 after purchasing an additional 5,882 shares in the last quarter. Bank of New York Mellon Corp raised its stake in scPharmaceuticals by 15.1% during the second quarter. Bank of New York Mellon Corp now owns 86,101 shares of the company’s stock valued at $375,000 after purchasing an additional 11,269 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in scPharmaceuticals during the third quarter valued at $57,000. Finally, Thrivent Financial for Lutherans raised its stake in scPharmaceuticals by 1.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after purchasing an additional 14,866 shares in the last quarter. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Trading Up 3.4 %

Shares of SCPH opened at $3.61 on Wednesday. scPharmaceuticals Inc. has a twelve month low of $3.08 and a twelve month high of $6.71. The company has a market cap of $180.64 million, a P/E ratio of -1.90 and a beta of 0.14. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The company’s fifty day simple moving average is $3.96 and its 200-day simple moving average is $4.38.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Craig Hallum reduced their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of scPharmaceuticals in a research note on Thursday, November 14th.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.